Nureca Quarterly Results
Nureca quarterly results. In Mar 2026, Nureca (NURECA) reported revenue ₹36 Cr and net profit ₹-6 Cr — revenue +5.9% YoY. Review NURECA P/E comparison to evaluate earnings-based valuation against sector peers.
NURECA Quarterly Results — Revenue, Profit & EPS Highlights
Nureca latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Nureca share price chart.
- Revenue of ₹36 Cr in Mar 2026 (-14.3% vs Jun 2026, +5.9% vs Mar 2025)
- Net Profit of ₹-6 Cr in Mar 2026 (-300.0% vs Jun 2026, -300.0% vs Mar 2025)
- EBITDA of ₹-5 Cr in Mar 2026 (-200.0% vs Jun 2026)
- Operating Margin of -16.0% in Mar 2026 (-24.0pp vs Jun 2026)
- Earnings Per Share of ₹-6.45 in Mar 2026 (-300.9% vs Jun 2026)
Nureca Quarterly Results — Revenue, EBITDA, Net Profit & EPS
NURECA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 36 | 42 | 40 | 34 | 37 | -14.3% | 5.9% |
| Net Profit (₹ Cr) | -6 | 3 | 4 | 3 | 1 | - | - |
| EBITDA (₹ Cr) | -5 | 5 | 6 | 3 | 2 | - | - |
| EPS (₹) | -6.45 | 3.21 | 3.63 | 2.47 | 0.81 | - | - |
| Operating Margin (%) | -16.0% | 8.0% | 9.0% | 4.0% | -2.0% | - | - |
NURECA Share Price Trend — 1-Year Movement Across Quarterly Results
Nureca 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Check Nureca market cap to track the company's total market size over time.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
NURECA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Nureca latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹421,995.00 Cr | 1748.0 | 15,018 | 2,710 | -5.6% | - | 18.0% | 154.7 |
|
Divis Laboratories
Mar 2026 |
₹241,231.30 Cr | 8950.0 | 2,986 | 751 | -5.0% | - | 25.2% | 316.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4524.4 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 393.1 |
|
Laurus Labs
Mar 2026 |
₹111,790.60 Cr | 1970.0 | 1,823 | 282 | -10.5% | - | 15.5% | 381.0 |
|
Zydus Life Science
Mar 2026 |
₹111,111.95 Cr | 1129.4 | 7,569 | 1,341 | -4.3% | - | 17.7% | 89.3 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores